Table 1. Demographic and clinical characteristics of control and patient groups.
| Parameters | Control (n=33) | HCM (n=51) | HT (n=51) | AL CA (n=63) | P value |
|---|---|---|---|---|---|
| Age (years) | 54±11 | 52±11 | 56±11 | 59±7 ‡ | <0.001 |
| Male | 13 (39.4) | 34 (66.7)† | 46 (90.2)†‡ | 42 (66.7)†§ | <0.001 |
| BMI (kg/m2) | 24.0±2.2 | 25.0±3.5 | 25.3±2.8 | 22.7±2.3†‡§ | <0.001 |
| BSA (m2) | 1.70±0.16 | 1.77±0.18 | 1.83±0.15† | 1.70±0.14 § | <0.001 |
| SBP (mmHg) | 123 (113, 133) | 136 (121, 150)† | 160 (143, 171)†‡ | 113 (104, 129) ‡§ | <0.001 |
| DBP (mmHg) | 72 (68, 82) | 85 (73, 97)† | 89 (80, 98)† | 72 (67, 77) ‡§ | <0.001 |
| HR (bpm) | 66 (60, 78) | 74 (66, 83) | 71 (64, 78) | 78 (73, 87)†§ | <0.001 |
| NYHA III–IV stage | – | 4/48 (8.3) | 8/51 (15.7) | 30/63 (47.6) ‡§ | <0.001 |
| NT-proBNP (pg/mL) | Р| 803 (202, 1,806) | 632 (54, 4,373) | 3,564 (564, 8,769) ठ| <0.001 |
| Troponin I (pg/mL) | Р| 20.8 (8.0, 47.5) | 9.1 (4.6, 26.2) | 59.9 (22.8, 150.9) ठ| <0.001 |
| eGFR (mL/min) | – | 83.1 (65.6, 100.9) | 62.4 (14.8, 91.9) ‡ | 69.5 (48.3, 89.0) ‡ | <0.001 |
Values are n (%), mean ± standard deviation, or median (interquartile range). †, P<0.05, versus healthy control; ‡, P<0.05, versus patients with HCM; §, P<0.05, versus patients with HT. HCM, hypertrophic cardiomyopathy; HT, hypertension; AL CA, light-chain cardiac amyloidosis; BMI, body mass index; BSA, body surface area; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; NYHA, New York Heart Association; NT-proBNP, n-terminal pro-B-type natriuretic protein; eGFR, estimated glomerular filtration rate.